IQVIA Q4 EPS of $3.42 Tops Estimates, Annual Profit Outlook Slips on Interest Costs
IQVIA reported Q4 2025 adjusted EPS of $3.42, beating the $3.40 consensus and up from $3.12 a year earlier. The company forecast full-year profit below analysts’ estimates due to higher interest expenses despite strong pharmaceutical client demand.
1. Q4 2025 Earnings Beat Street Estimates
IQVIA reported fourth-quarter adjusted earnings of $3.42 per share, surpassing the Zacks Consensus Estimate of $3.40 and up 9.6% from $3.12 in Q4 2024. Revenue rose in the low double digits year-over-year, driven by strong contributions from both its Technology & Analytics Solutions and Contract Research Organization segments. CFO Ronald Bruehlman highlighted disciplined cost management that improved margins by 120 basis points sequentially.
2. Double-Digit Year-Over-Year Revenue Growth
Total Q4 revenue increased by 11.3% compared with the prior year quarter. The Technology & Analytics Solutions division posted 13.5% growth, with Real-World Evidence services and cloud-based data offerings each expanding by more than 15%. The Contract Research Organization segment saw 9.2% growth, supported by accelerated study starts in oncology and immunology.
3. Segment Profitability and Margin Expansion
IQVIA’s adjusted operating margin expanded to 19.8% in Q4, up from 18.6% a year ago. Margin improvement was driven by higher utilization in CRO operations and scalable software revenue in its analytics business. Gross profit in the Analytics segment increased 17%, while SG&A expenses grew only 5%, reflecting leverage on fixed costs.
4. 2026 Outlook Tempered by Rising Interest Expenses
For fiscal 2026, IQVIA forecast revenue growth of 10% to 12% and adjusted EPS of $13.80 to $14.00, slightly below consensus of $14.10. Management attributed the EPS headwind to a projected 15% increase in net interest expense to approximately $330 million, stemming from recent debt issuances to fund strategic acquisitions and share repurchases.